Anxiety Disorders And Depression Treatment Market
Growing depression cases to catalyze the growth of Anxiety Disorders and Depression Treatment Market: Opportunities ahead
Anxiety Disorders And Depression Treatment Market by Drug Class, Indication, Distribution Channel & Region | Forecast 2022 to 2032
Anxiety Disorders And Depression Treatment Market Overview (2023 to 2033)
The global Anxiety Disorders and Depression Treatment Market was valued at around US$ 11.2 billion in 2021. With a projected CAGR of 3.4% for the next ten years, the market is likely to reach a valuation of nearly US$ 16.1 billion by the end of 2032. In the upcoming years, market growth is anticipated to be accelerated by efforts made jointly by pharmaceutical firms, NGOs, mental health groups, and government initiatives to raise public awareness.
|
Report Attributes |
Details |
|
Anxiety Disorders And Depression Treatment Market Size (2021A) |
US$ 11.2 billion |
|
Estimated Market Value (2022E) |
US$ 11.5 billion |
|
Forecasted Market Value (2032F) |
US$ 16.1 billion |
|
Global Market Growth Rate (2022 to 2032) |
3.4% CAGR |
|
United States Growth Rate (2022 to 2032) |
3.2% CAGR |
|
Key Companies Covered |
|
Future Market Insights’ analysis reveals that in 2022 revenue through the Anxiety Disorders and Depression Treatment Market is estimated at US$ 11.5 billion. Worldwide, due to the enormous financial and emotional strain on people, families, and society as a whole, mental health illnesses are becoming more prevalent among adults. The WHO estimates that the cost of mental health issues in affluent nations ranges from 3% to 4% of GDP. As a result, the government's goal of lessening the financial burden of these disorders is likely to spur product demand and ensure prompt management of anxiety and depression.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales Analysis of Anxiety Disorders and Depression Treatment Market from 2015 to 2021 Vs Market Outlook for 2022 to 2032
The global market for Anxiety Disorders and Depression Treatment Market expanded at a CAGR of 2.7% from 2015 to 2021. Around 284 million people worldwide suffer from anxiety, yet only 36% of them seek therapy, according to MindMed research.
Sales of anxiety and depression-related disease products and clinical trials are increasing in the global market because of the demand for appropriate management of these disorders as well as strong outreach activities. The United States will continue to be the largest user of anxiety disorder and depression treatment products throughout the analysis period accounting for over US$ 1.5 billion absolute dollar opportunity in the coming 10-year period.
How are key drivers going to affect the Anxiety Disorders and Depression Treatment Market?
Strong support for Research and Development (R&D) funding from the government and international healthcare organizations has spurred the revenue growth of the anxiety disorders and depression treatment market. Around 76 thousand grants for mental health were active between 2015 and 2020 from 345 funders in 38 nations. About 5% of all registered grants and 4% of the overall research spending, or US$ 18.5 billion, were related to mental health. With 89%, high-income nations received the majority of investments while the United States provided 39% of all grants. These investments are probably expected to help the market for treating anxiety disorders and depression in several ways.
Globally, patient care for mental health diseases is being enhanced through research and development. There are now more candidates for the treatment of anxiety disorders and depression in the pipeline owing to innovative research that has resulted in combination therapies using novel or existing medication molecules. For instance, the USA FDA recently approved LY03005, an antidepressant medicine manufactured by Luye Pharma.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the restraints to the growth of the Anxiety Disorders and Depression Treatment Market?
High drug dosages used to treat damaged neurological cells typically cause harm to healthy cells in the body. Many people experience a variety of negative effects as a result of these, including weight gain, impaired vision, nausea, dizziness, and others.
As a result, these side effects from anxiety and depression medications are having a detrimental impact on the demand for therapy, and the unavailability of resources available is another issue impeding market expansion. For instance, according to WHO research, between 44% and 70% of patients in industrialized countries do not obtain treatment, whereas in developing countries the difference is significantly greater and is close to 90%.
Region-wise Insights
In what ways does the Anxiety Disorders and Depression Treatment Market in North America have a bright future?
Due to the availability of numerous branded formulations impacting the market dynamics, North America accounts for the largest market share of anxiety disorders and depression treatment accounting for over 45%. As a result of the present pandemic, the demand for therapies for anxiety disorders and depression has increased. For instance, according to Bloomberg, the prescription rate for the anti-anxiety medication Zoloft increased by 12% in March 2020. Lockdowns, financial hardships, and a lack of physical contact have been cited as the main causes of a significant rise in depression and anxiety cases in North America.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Country-wise Insights
The USA Anxiety Disorders and Depression Treatment Market Analysis
The United States will account for US$ 5.6 billion of the global Anxiety Disorders and Depression Treatment Market by 2032. Anxiety Disorders and Depression Treatment Market growth in the USA from 2015 to 2021 was estimated at 2.3% CAGR. Researchers from Boston University found that half of the adults polled in the USA in September 2020 showed some symptoms of depression, such as feelings of helplessness and failure. These alarming statistics promise a further higher market for anxiety disorders and depression treatment market in the country.
The United Kingdom Anxiety Disorders and Depression Treatment Market Analysis
The anxiety Disorders and Depression market in the United Kingdom are expected to reach a valuation of US$ 665.5 million by 2032. The market in the country is projected to gross an absolute dollar opportunity of US$ 141.2 million from 2022 to 2032 and register a CAGR of 2.4%.
Japan Anxiety Disorders and Depression Treatment Market Analysis
The market in Japan is expected to garner an absolute dollar opportunity of US$ 151.8 million in 2022. The market in the country is expected to reach a valuation of US$ 932.2 million by 2032, growing at a CAGR of 1.8% from 2022 to 2032.
South Korea Anxiety Disorders and Depression Treatment Market Analysis
The market in South Korea is expected to expand at a CAGR of 1.4% from 2022 to 2032. The market is expected to swell at an absolute dollar opportunity of US$ 77.2 million from 2022 to 2032. By 2032, the market in the country is likely to reach a valuation of US$ 566.8 million.
Category-wise Insights
Why is depression taking center stage in the global Anxiety Disorders and Depression Treatment Market?
The market growth through the depression segment expanded at a CAGR of 2.4% from 2015 to 2021. According to WHO, depression affects an estimated 3.8% of the world's population, including 5% of adults and 5.7% of persons over the age of 60. Suicide can result from depression at its worst. Every year, suicide claims the lives of more than 700 thousand people. For people aged 15 to 29, suicide is the fourth most common cause of death. More than 75.0% of people in low- and middle-income countries do not obtain treatment for mental problems despite the fact that there are well-established, efficient treatments.
Competitive Landscape
Companies that offer treatment for anxiety disorders and depression frequently form joint ventures, buy sister companies, and work to obtain the FDA to approve their treatments. There has also been a significant investment in R&D for some cutting-edge products.
The key companies operating in the Anxiety Disorders and Depression Treatment Market include Pfizer Inc, H. Lundbeck A/S, Glaxo SmithKline pharmaceuticals ltd, Merck & Co., Inc, Eli Lilly & Company, AstraZeneca, H. Lundbeck A/S, Bristol-Myers Squibb, Johnson & Johnson, AbbVie Inc., Sanofi, Novartis AG, Forest Laboratories, Inc., Alembic pharma, Janssen Pharmaceutical N.V., and Cadent Therapeutics.
Some of the recent developments by key providers of the Anxiety Disorders and Depression Treatment Market are as follows:
- In July 2021, Desipramine hydrochloride tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg were approved by the US FDA for the treatment of depression.
- In May 2021, the PALISADE-a phase 3 trials, a randomized, double-blind, placebo-controlled research to assess the efficacy and safety of PH94B for the acute treatment of anxiety in people with a social anxiety disorder, was launched as part of VisataGen Therapeutics Inc.'s PALISADE Phase-3 clinical program (SAD).
- In November 2020, in order to aid patients with treatment-resistant major depressive disorder, Janssen Pharmaceutical N.V. worked with the mental healthcare provider Koa Health to conduct research on how to give digital cognitive behavioral therapy alongside pharmacological treatment.
- In August 2020, the USA Food And Drug Administration (FDA) approved an application to add intranasal SPRAVATO, a nasal spray, with an oral antidepressant to Treat depressive symptoms in adults with major depressive disorder and abrupt suicidal ideation or behavior. This was announced by Janssen Pharmaceuticals N.V.
- In June 2020, an agreement was reached between Neurocrine Bioscience, Inc. and Takeda Pharmaceutical Company Limited to work together on developing new treatments for psychiatric diseases.
- In December 2020, Novartis announced that it would acquire Cadent Therapeutics for up to US$ 770 million in total consideration. With the acquisition, Novartis will be able to take advantage of Cadent's full neuroscience portfolio and increase its market share in the field of mental health.
- In December 2020, a merger deal was signed by Big Rock Partners Acquisition Corp. and NeuroRx, a company developing cutting-edge treatments for COVID-19 and bipolar illness.
- In December 2020, the European Medicines Agency (EMA) accepted H. Lundbeck A/submission S's for Vyepti for assessment of the Marketing Authorization Application (MAA). The application asks for permission to make Vyepti available to European residents who suffer from migraine and are qualified for preventative therapy. The goal of Vyepti is to stop calcitonin gene-related peptide (CGRP) from interacting with its receptor, which will stop migraine attacks.
Similarly, recent developments related to companies providing services for Anxiety Disorders and Depression Treatment have been tracked by the team at Future Market Insights, which is available in the full report.
Key Segments Covered in Anxiety Disorders and Depression Treatment Market Survey
Anxiety Disorders and Depression Treatment Market by Drug Class:
- Antidepressants
- Anxiolytics
- Anticonvulsants
- Noradrenergic Agents
- Atypical Antipsychotics
Anxiety Disorders and Depression Treatment Market by Indication:
- Anxiety
- Depression
Anxiety Disorders and Depression Treatment Market by Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Anxiety Disorders and Depression Treatment Market by Region:
- North America
- Latin America
- Europe Anxiety
- Asia Pacific Anxiety
- Middle East & Africa
Frequently Asked Questions
How much is the global Anxiety Disorders and Depression Treatment Market currently worth?
The global Anxiety Disorders and Depression Treatment Market was valued at US$ 11.2 billion in 2021.
What is the Anxiety Disorders and Depression Treatment Market Forecast through 2032?
The Anxiety Disorders and Depression Treatment Market is set to witness a growth rate of 3.4% over the forecast period and be valued at US$ 16.1 billion by 2032.
At what rate did demand for Anxiety Disorders and Depression Treatment Market increase over the past 6 years?
The Anxiety Disorders and Depression Treatment Market expanded by CAGR 2.7% from 2015 through 2021.
Who are the key players shaping the Anxiety Disorders and Depression Treatment Market?
The key players in the Anxiety Disorders and Depression Treatment Market are Pfizer Inc, H. Lundbeck A/S, Glaxo Smithkline Pharmaceuticals Ltd, Merc Co Inc, Eli Lilly & Company.
Who are the top 5 countries driving the highest sales in the Anxiety Disorders and Depression Treatment Market?
United States, United Kingdom, China, Japan, and South Korea are expected to drive the most sales growth in the Anxiety Disorders and Depression Treatment Market.
What is the China market outlook for Anxiety Disorders and Depression Treatment?
The Anxiety Disorders and Depression Treatment Market in China account for US$ 665.6 Mn of the global market share by end of the forecast year.
Which country has the largest market share of the Anxiety Disorders and Depression Treatment Market?
The United States held the largest market share of the Anxiety Disorders and Depression Treatment Market with US$ 1.5 billion of absolute dollar opportunity.
Table of Content
1. Executive Summary | Anxiety Disorders And Depression Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Investment Feasibility Matrix 3.4. PESTLE and Porter’s Analysis 3.5. Regulatory Landscape 3.5.1. By Key Regions 3.5.2. By Key Countries 4. Global Market Analysis 2015 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ million) Analysis, 2015 to 2021 4.2. Current and Future Market Size Value (US$ million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ million) Analysis By Drug Class, 2015 to 2021 5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Drug Class, 2022 to 2032 5.3.1. Antidepressants 5.3.2. Anxiolytics 5.3.3. Anticonvulsants 5.3.4. Noradrenergic Agents 5.3.5. Atypical Antipsychotics 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2015 to 2021 5.5. Absolute $ Opportunity Analysis By Drug Class, 2022 to 2032 6. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ million) Analysis By Indication, 2015 to 2021 6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Indication, 2022 to 2032 6.3.1. Anxiety 6.3.2. Depression 6.4. Y-o-Y Growth Trend Analysis By Indication, 2015 to 2021 6.5. Absolute $ Opportunity Analysis By Indication, 2022 to 2032 7. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ million) Analysis By Distribution Channel, 2015 to 2021 7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Distribution Channel, 2022 to 2032 7.3.1. Hospital Pharmacy 7.3.2. Retail Pharmacy 7.3.3. Online pharmacy 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2015 to 2021 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022 to 2032 8. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ million) Analysis By Region, 2015 to 2021 8.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2022 to 2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. East Asia 8.3.5. South Asia 8.3.6. Oceania 8.3.7. Middle East and Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 9.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021 9.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 9.2.1. By Country 9.2.1.1. The USA 9.2.1.2. Canada 9.2.2. By Drug Class 9.2.3. By Indication 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Indication 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021 10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Argentina 10.2.1.4. Rest of Latin America 10.2.2. By Drug Class 10.2.3. By Indication 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Indication 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021 11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. Italy 11.2.1.3. France 11.2.1.4. The United Kingdom 11.2.1.5. Spain 11.2.1.6. Russia 11.2.1.7. BENELUX 11.2.1.8. Rest of Europe 11.2.2. By Drug Class 11.2.3. By Indication 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Indication 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. East Asia Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021 12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Drug Class 12.2.3. By Indication 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Indication 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. South Asia Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021 13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Thailand 13.2.1.3. Malaysia 13.2.1.4. Indonesia 13.2.1.5. Rest of South Asia 13.2.2. By Drug Class 13.2.3. By Indication 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Indication 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021 14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Class 14.2.3. By Indication 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Indication 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. MEA Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021 15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 15.2.1. By Country 15.2.1.1. GCC 15.2.1.2. Rest of MEA 15.2.2. By Drug Class 15.2.3. By Indication 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Indication 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. The USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2021 16.1.2.1. By Drug Class 16.1.2.2. By Indication 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2021 16.2.2.1. By Drug Class 16.2.2.2. By Indication 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2021 16.3.2.1. By Drug Class 16.3.2.2. By Indication 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2021 16.4.2.1. By Drug Class 16.4.2.2. By Indication 16.4.2.3. By Distribution Channel 16.5. Argentina 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2021 16.5.2.1. By Drug Class 16.5.2.2. By Indication 16.5.2.3. By Distribution Channel 16.6. Germany 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2021 16.6.2.1. By Drug Class 16.6.2.2. By Indication 16.6.2.3. By Distribution Channel 16.7. Italy 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2021 16.7.2.1. By Drug Class 16.7.2.2. By Indication 16.7.2.3. By Distribution Channel 16.8. France 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2021 16.8.2.1. By Drug Class 16.8.2.2. By Indication 16.8.2.3. By Distribution Channel 16.9. The United Kingdom 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2021 16.9.2.1. By Drug Class 16.9.2.2. By Indication 16.9.2.3. By Distribution Channel 16.10. Spain 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2021 16.10.2.1. By Drug Class 16.10.2.2. By Indication 16.10.2.3. By Distribution Channel 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2021 16.11.2.1. By Drug Class 16.11.2.2. By Indication 16.11.2.3. By Distribution Channel 16.12. BENELUX 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2021 16.12.2.1. By Drug Class 16.12.2.2. By Indication 16.12.2.3. By Distribution Channel 16.13. China 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2021 16.13.2.1. By Drug Class 16.13.2.2. By Indication 16.13.2.3. By Distribution Channel 16.14. Japan 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2021 16.14.2.1. By Drug Class 16.14.2.2. By Indication 16.14.2.3. By Distribution Channel 16.15. South Korea 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2021 16.15.2.1. By Drug Class 16.15.2.2. By Indication 16.15.2.3. By Distribution Channel 16.16. India 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2021 16.16.2.1. By Drug Class 16.16.2.2. By Indication 16.16.2.3. By Distribution Channel 16.17. Thailand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2021 16.17.2.1. By Drug Class 16.17.2.2. By Indication 16.17.2.3. By Distribution Channel 16.18. Malaysia 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2021 16.18.2.1. By Drug Class 16.18.2.2. By Indication 16.18.2.3. By Distribution Channel 16.19. Indonesia 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2021 16.19.2.1. By Drug Class 16.19.2.2. By Indication 16.19.2.3. By Distribution Channel 16.20. Australia 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2021 16.20.2.1. By Drug Class 16.20.2.2. By Indication 16.20.2.3. By Distribution Channel 16.21. New Zealand 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2021 16.21.2.1. By Drug Class 16.21.2.2. By Indication 16.21.2.3. By Distribution Channel 16.22. GCC Countries 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2021 16.22.2.1. By Drug Class 16.22.2.2. By Indication 16.22.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Class 17.3.3. By Indication 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Pfizer Inc. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.1.5.2. Product Strategy 18.1.1.5.3. Channel Strategy 18.1.2. H. Lundbeck A/S 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.2.5.2. Product Strategy 18.1.2.5.3. Channel Strategy 18.1.3. Glaxo smithkline pharmaceuticals ltd. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.3.5.2. Product Strategy 18.1.3.5.3. Channel Strategy 18.1.4. Merc Co Inc. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.4.5.2. Product Strategy 18.1.4.5.3. Channel Strategy 18.1.5. Merc Co Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.5.5.2. Product Strategy 18.1.5.5.3. Channel Strategy 18.1.6. Eli Lilly & Company 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.6.5.2. Product Strategy 18.1.6.5.3. Channel Strategy 18.1.7. AstraZeneca 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.7.5.2. Product Strategy 18.1.7.5.3. Channel Strategy 18.1.8. H. Lundbeck A/S 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.8.5.2. Product Strategy 18.1.8.5.3. Channel Strategy 18.1.9. Bristol-Myers Squibb 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.9.5.2. Product Strategy 18.1.9.5.3. Channel Strategy 18.1.10. Johnson & Johnson 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.10.5.2. Product Strategy 18.1.10.5.3. Channel Strategy 18.1.11. AbbVie Inc. 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.11.5.2. Product Strategy 18.1.11.5.3. Channel Strategy 18.1.12. Sanofi 18.1.12.1. Overview 18.1.12.2. Product Portfolio 18.1.12.3. Profitability by Market Segments 18.1.12.4. Sales Footprint 18.1.12.5. Strategy Overview 18.1.12.5.1. Marketing Strategy 18.1.12.5.2. Product Strategy 18.1.12.5.3. Channel Strategy 18.1.13. Novartis AG 18.1.13.1. Overview 18.1.13.2. Product Portfolio 18.1.13.3. Profitability by Market Segments 18.1.13.4. Sales Footprint 18.1.13.5. Strategy Overview 18.1.13.5.1. Marketing Strategy 18.1.13.5.2. Product Strategy 18.1.13.5.3. Channel Strategy 18.1.14. Forest Laboratories, Inc. 18.1.14.1. Overview 18.1.14.2. Product Portfolio 18.1.14.3. Profitability by Market Segments 18.1.14.4. Sales Footprint 18.1.14.5. Strategy Overview 18.1.14.5.1. Marketing Strategy 18.1.14.5.2. Product Strategy 18.1.14.5.3. Channel Strategy 18.1.15. Alembic Pharma 18.1.15.1. Overview 18.1.15.2. Product Portfolio 18.1.15.3. Profitability by Market Segments 18.1.15.4. Sales Footprint 18.1.15.5. Strategy Overview 18.1.15.5.1. Marketing Strategy 18.1.15.5.2. Product Strategy 18.1.15.5.3. Channel Strategy 18.1.16. Janssen Pharmaceutical N.V. 18.1.16.1. Overview 18.1.16.2. Product Portfolio 18.1.16.3. Profitability by Market Segments 18.1.16.4. Sales Footprint 18.1.16.5. Strategy Overview 18.1.16.5.1. Marketing Strategy 18.1.16.5.2. Product Strategy 18.1.16.5.3. Channel Strategy 18.1.17. Cadent Therapeutics 18.1.17.1. Overview 18.1.17.2. Product Portfolio 18.1.17.3. Profitability by Market Segments 18.1.17.4. Sales Footprint 18.1.17.5. Strategy Overview 18.1.17.5.1. Marketing Strategy 18.1.17.5.2. Product Strategy 18.1.17.5.3. Channel Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ million) Forecast by Region, 2015 to 2032 Table 2: Global Market Value (US$ million) Forecast by Drug Class, 2015 to 2032 Table 3: Global Market Value (US$ million) Forecast by Indication, 2015 to 2032 Table 4: Global Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032 Table 5: North America Market Value (US$ million) Forecast by Country, 2015 to 2032 Table 6: North America Market Value (US$ million) Forecast by Drug Class, 2015 to 2032 Table 7: North America Market Value (US$ million) Forecast by Indication, 2015 to 2032 Table 8: North America Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032 Table 9: Latin America Market Value (US$ million) Forecast by Country, 2015 to 2032 Table 10: Latin America Market Value (US$ million) Forecast by Drug Class, 2015 to 2032 Table 11: Latin America Market Value (US$ million) Forecast by Indication, 2015 to 2032 Table 12: Latin America Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032 Table 13: Europe Market Value (US$ million) Forecast by Country, 2015 to 2032 Table 14: Europe Market Value (US$ million) Forecast by Drug Class, 2015 to 2032 Table 15: Europe Market Value (US$ million) Forecast by Indication, 2015 to 2032 Table 16: Europe Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032 Table 17: East Asia Market Value (US$ million) Forecast by Country, 2015 to 2032 Table 18: East Asia Market Value (US$ million) Forecast by Drug Class, 2015 to 2032 Table 19: East Asia Market Value (US$ million) Forecast by Indication, 2015 to 2032 Table 20: East Asia Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032 Table 21: South Asia Market Value (US$ million) Forecast by Country, 2015 to 2032 Table 22: South Asia Market Value (US$ million) Forecast by Drug Class, 2015 to 2032 Table 23: South Asia Market Value (US$ million) Forecast by Indication, 2015 to 2032 Table 24: South Asia Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032 Table 25: Oceania Market Value (US$ million) Forecast by Country, 2015 to 2032 Table 26: Oceania Market Value (US$ million) Forecast by Drug Class, 2015 to 2032 Table 27: Oceania Market Value (US$ million) Forecast by Indication, 2015 to 2032 Table 28: Oceania Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032 Table 29: MEA Market Value (US$ million) Forecast by Country, 2015 to 2032 Table 30: MEA Market Value (US$ million) Forecast by Drug Class, 2015 to 2032 Table 31: MEA Market Value (US$ million) Forecast by Indication, 2015 to 2032 Table 32: MEA Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ million) by Drug Class, 2022 to 2032 Figure 2: Global Market Value (US$ million) by Indication, 2022 to 2032 Figure 3: Global Market Value (US$ million) by Distribution Channel, 2022 to 2032 Figure 4: Global Market Value (US$ million) by Region, 2022 to 2032 Figure 5: Global Market Value (US$ million) Analysis by Region, 2015 to 2032 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032 Figure 8: Global Market Value (US$ million) Analysis by Drug Class, 2015 to 2032 Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032 Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032 Figure 11: Global Market Value (US$ million) Analysis by Indication, 2015 to 2032 Figure 12: Global Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032 Figure 13: Global Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032 Figure 14: Global Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032 Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032 Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032 Figure 17: Global Market Attractiveness by Drug Class, 2022 to 2032 Figure 18: Global Market Attractiveness by Indication, 2022 to 2032 Figure 19: Global Market Attractiveness by Distribution Channel, 2022 to 2032 Figure 20: Global Market Attractiveness by Region, 2022 to 2032 Figure 21: North America Market Value (US$ million) by Drug Class, 2022 to 2032 Figure 22: North America Market Value (US$ million) by Indication, 2022 to 2032 Figure 23: North America Market Value (US$ million) by Distribution Channel, 2022 to 2032 Figure 24: North America Market Value (US$ million) by Country, 2022 to 2032 Figure 25: North America Market Value (US$ million) Analysis by Country, 2015 to 2032 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 28: North America Market Value (US$ million) Analysis by Drug Class, 2015 to 2032 Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032 Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032 Figure 31: North America Market Value (US$ million) Analysis by Indication, 2015 to 2032 Figure 32: North America Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032 Figure 33: North America Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032 Figure 34: North America Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032 Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032 Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032 Figure 37: North America Market Attractiveness by Drug Class, 2022 to 2032 Figure 38: North America Market Attractiveness by Indication, 2022 to 2032 Figure 39: North America Market Attractiveness by Distribution Channel, 2022 to 2032 Figure 40: North America Market Attractiveness by Country, 2022 to 2032 Figure 41: Latin America Market Value (US$ million) by Drug Class, 2022 to 2032 Figure 42: Latin America Market Value (US$ million) by Indication, 2022 to 2032 Figure 43: Latin America Market Value (US$ million) by Distribution Channel, 2022 to 2032 Figure 44: Latin America Market Value (US$ million) by Country, 2022 to 2032 Figure 45: Latin America Market Value (US$ million) Analysis by Country, 2015 to 2032 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 48: Latin America Market Value (US$ million) Analysis by Drug Class, 2015 to 2032 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032 Figure 51: Latin America Market Value (US$ million) Analysis by Indication, 2015 to 2032 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032 Figure 54: Latin America Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032 Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032 Figure 57: Latin America Market Attractiveness by Drug Class, 2022 to 2032 Figure 58: Latin America Market Attractiveness by Indication, 2022 to 2032 Figure 59: Latin America Market Attractiveness by Distribution Channel, 2022 to 2032 Figure 60: Latin America Market Attractiveness by Country, 2022 to 2032 Figure 61: Europe Market Value (US$ million) by Drug Class, 2022 to 2032 Figure 62: Europe Market Value (US$ million) by Indication, 2022 to 2032 Figure 63: Europe Market Value (US$ million) by Distribution Channel, 2022 to 2032 Figure 64: Europe Market Value (US$ million) by Country, 2022 to 2032 Figure 65: Europe Market Value (US$ million) Analysis by Country, 2015 to 2032 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 68: Europe Market Value (US$ million) Analysis by Drug Class, 2015 to 2032 Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032 Figure 71: Europe Market Value (US$ million) Analysis by Indication, 2015 to 2032 Figure 72: Europe Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032 Figure 73: Europe Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032 Figure 74: Europe Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032 Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032 Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032 Figure 77: Europe Market Attractiveness by Drug Class, 2022 to 2032 Figure 78: Europe Market Attractiveness by Indication, 2022 to 2032 Figure 79: Europe Market Attractiveness by Distribution Channel, 2022 to 2032 Figure 80: Europe Market Attractiveness by Country, 2022 to 2032 Figure 81: East Asia Market Value (US$ million) by Drug Class, 2022 to 2032 Figure 82: East Asia Market Value (US$ million) by Indication, 2022 to 2032 Figure 83: East Asia Market Value (US$ million) by Distribution Channel, 2022 to 2032 Figure 84: East Asia Market Value (US$ million) by Country, 2022 to 2032 Figure 85: East Asia Market Value (US$ million) Analysis by Country, 2015 to 2032 Figure 86: East Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 88: East Asia Market Value (US$ million) Analysis by Drug Class, 2015 to 2032 Figure 89: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032 Figure 90: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032 Figure 91: East Asia Market Value (US$ million) Analysis by Indication, 2015 to 2032 Figure 92: East Asia Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032 Figure 93: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032 Figure 94: East Asia Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032 Figure 95: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032 Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032 Figure 97: East Asia Market Attractiveness by Drug Class, 2022 to 2032 Figure 98: East Asia Market Attractiveness by Indication, 2022 to 2032 Figure 99: East Asia Market Attractiveness by Distribution Channel, 2022 to 2032 Figure 100: East Asia Market Attractiveness by Country, 2022 to 2032 Figure 101: South Asia Market Value (US$ million) by Drug Class, 2022 to 2032 Figure 102: South Asia Market Value (US$ million) by Indication, 2022 to 2032 Figure 103: South Asia Market Value (US$ million) by Distribution Channel, 2022 to 2032 Figure 104: South Asia Market Value (US$ million) by Country, 2022 to 2032 Figure 105: South Asia Market Value (US$ million) Analysis by Country, 2015 to 2032 Figure 106: South Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 107: South Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 108: South Asia Market Value (US$ million) Analysis by Drug Class, 2015 to 2032 Figure 109: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032 Figure 110: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032 Figure 111: South Asia Market Value (US$ million) Analysis by Indication, 2015 to 2032 Figure 112: South Asia Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032 Figure 113: South Asia Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032 Figure 114: South Asia Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032 Figure 115: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032 Figure 116: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032 Figure 117: South Asia Market Attractiveness by Drug Class, 2022 to 2032 Figure 118: South Asia Market Attractiveness by Indication, 2022 to 2032 Figure 119: South Asia Market Attractiveness by Distribution Channel, 2022 to 2032 Figure 120: South Asia Market Attractiveness by Country, 2022 to 2032 Figure 121: Oceania Market Value (US$ million) by Drug Class, 2022 to 2032 Figure 122: Oceania Market Value (US$ million) by Indication, 2022 to 2032 Figure 123: Oceania Market Value (US$ million) by Distribution Channel, 2022 to 2032 Figure 124: Oceania Market Value (US$ million) by Country, 2022 to 2032 Figure 125: Oceania Market Value (US$ million) Analysis by Country, 2015 to 2032 Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 128: Oceania Market Value (US$ million) Analysis by Drug Class, 2015 to 2032 Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032 Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032 Figure 131: Oceania Market Value (US$ million) Analysis by Indication, 2015 to 2032 Figure 132: Oceania Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032 Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032 Figure 134: Oceania Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032 Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032 Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032 Figure 137: Oceania Market Attractiveness by Drug Class, 2022 to 2032 Figure 138: Oceania Market Attractiveness by Indication, 2022 to 2032 Figure 139: Oceania Market Attractiveness by Distribution Channel, 2022 to 2032 Figure 140: Oceania Market Attractiveness by Country, 2022 to 2032 Figure 141: MEA Market Value (US$ million) by Drug Class, 2022 to 2032 Figure 142: MEA Market Value (US$ million) by Indication, 2022 to 2032 Figure 143: MEA Market Value (US$ million) by Distribution Channel, 2022 to 2032 Figure 144: MEA Market Value (US$ million) by Country, 2022 to 2032 Figure 145: MEA Market Value (US$ million) Analysis by Country, 2015 to 2032 Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 148: MEA Market Value (US$ million) Analysis by Drug Class, 2015 to 2032 Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032 Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032 Figure 151: MEA Market Value (US$ million) Analysis by Indication, 2015 to 2032 Figure 152: MEA Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032 Figure 153: MEA Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032 Figure 154: MEA Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032 Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032 Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032 Figure 157: MEA Market Attractiveness by Drug Class, 2022 to 2032 Figure 158: MEA Market Attractiveness by Indication, 2022 to 2032 Figure 159: MEA Market Attractiveness by Distribution Channel, 2022 to 2032 Figure 160: MEA Market Attractiveness by Country, 2022 to 2032
Recommendations
Explore Healthcare Insights
View Reports
